Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Accumulated Expenses: 2022-2024

Historic Accumulated Expenses for Orchestra BioMed Holdings (OBIO) over the last 3 years, with Dec 2024 value amounting to $6.1 million.

  • Orchestra BioMed Holdings' Accumulated Expenses fell 2.80% to $6.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.8 million, marking a year-over-year decrease of 2.80%. This contributed to the annual value of $6.1 million for FY2024, which is 18.16% up from last year.
  • Latest data reveals that Orchestra BioMed Holdings reported Accumulated Expenses of $6.1 million as of FY2024, which was up 18.16% from $5.1 million recorded in FY2023.
  • Orchestra BioMed Holdings' Accumulated Expenses' 5-year high stood at $6.1 million during FY2024, with a 5-year trough of $5.1 million in FY2023.
  • In the last 3 years, Orchestra BioMed Holdings' Accumulated Expenses had a median value of $5.4 million in 2022 and averaged $5.5 million.
  • Per our database at Business Quant, Orchestra BioMed Holdings' Accumulated Expenses decreased by 4.22% in 2023 and then grew by 18.16% in 2024.
  • Over the past 3 years, Orchestra BioMed Holdings' Accumulated Expenses (Yearly) stood at $5.4 million in 2022, then dropped by 4.22% to $5.1 million in 2023, then grew by 18.16% to $6.1 million in 2024.